The histone demethylase LSD1 (KDM1A) demethylates mono-and di-methylated (Me2) lysine (K) 4 on histone H3. High LSD1 expression blocks differentiation and confers a poor prognosis in acute myeloid leukemia (AML). Here, treatment with the novel LSD1 antagonist SP2509 attenuated the binding of LSD1 with the corepressor CoREST, increased the permissive H3K4Me3 mark on the target gene promoters, and increased the levels of p21, p27 and CCAAT/enhancer binding protein a in cultured AML cells. In addition, SP2509 treatment or LSD1 shRNA inhibited the colony growth of AML cells. SP2509 also induced morphological features of differentiation in the cultured and primary AML blasts. SP2509 induced more apoptosis of AML cells expressing mutant NPM1 than mixed-lineage leukemia fusion oncoproteins. Treatment with SP2509 alone significantly improved the survival of immunedepleted mice following tail-vein infusion and engraftment of cultured or primary human AML cells. Co-treatment with pan-HDAC inhibitor (HDI) panobinostat (PS) and SP2509 was synergistically lethal against cultured and primary AML blasts. Compared with each agent alone, co-treatment with SP2509 and PS significantly improved the survival of the mice engrafted with the human AML cells, without exhibiting any toxicity. Collectively, these findings show that the combination of LSD1 antagonist and pan-HDI is a promising therapy warranting further testing against AML.
INTRODUCTION
Following standard chemotherapy, while complete remissions are routinely achieved, a majority of patients with acute myeloid leukemia (AML) eventually suffer relapse with treatment-refractory disease. 1 Consequently, the overall 5-year survival of AML patients remains B23%, creating a compelling rationale to develop novel therapeutics for AML. 2 In the pathogenesis of AML, multiple mechanisms involving genetic alterations and epigenetic deregulations collaborate to cause aberrant maturation arrest, growth and survival of early myeloid progenitor cells. 3, 4 Among the deregulated epigenetic mechanisms, in addition to DNA methylation and histone (H) deacetylation, alterations in histone H3 lysine (K)-specific methylation are involved in promoting the aberrant gene expression or 'transcriptome' in AML cells, which includes the deregulated expression of oncogenes and tumor suppressor genes. 5, 6 Although the levels H3K27 trimethylation (3Me) and H3K9Me3 are among the repressive chromatin marks, H3K4Me3 is a permissive histone modification that promotes gene transcription. 3, 6 LSD1 (KDM1A) is an FAD-dependent histone demethylase, with homology to amine oxidases, which demethylates di-and mono-methylated K4 on histone H3, reducing the permissive H3K4Me3. 7, 8 LSD1 is known to interact with the corepressor complex CoREST, containing RE1-silencing transcription factor (REST) and the histone deacetylases (HDAC) 1 and 2, which augments the gene repressor activity of LSD1. 9, 10 High LSD1 expression has been shown to confer poor prognosis in cancers. 11, 12 LSD1 has also been shown to demethylate nonhistone products most notably p53 and DNMT1, which improves their stability. [13] [14] [15] Although the null mutation of LSD1 is embryonically lethal, 15 LSD1 inhibition has been shown to attenuate growth of pluripotent cancer cells by repressing OCT4 and SOX2. 16 A recent report demonstrated that LSD1 inhibition increased H3K4Me2 levels and induced the expression of myeloid differentiation-associated genes. 17 Co-treatment with the LSD1 inhibitor tranylcypromine (TCP), which also inhibits monoamine oxidase (MAO) A and B, and all-trans-retinoic acid was shown to diminish the engraftment of primary AML cells in vivo in the NOD/ SCID-IL-2receptor-g-deficient (NSG) mice. 17 Also, LSD1 inhibition with a TCP analog phenocopied LSD1 knockdown in primary AML cells expressing mixed-lineage leukemia (MLL) fusion oncoprotein. 18 Furthermore, LSD1 was shown to sustain the leukemogenic potential of the MLL-AF9 leukemia stem cells. 18 Collectively, these reports strongly suggest that targeted knockdown of LSD1 levels and activity induces differentiation and exerts anti-AML activity. However, in each report, the LSD1 inhibitor used exhibited severe in vivo toxicity at the concentration that inhibited LSD1 activity and reduced the AML burden. 17, 18 SP2509 is a novel, FAD-binding pocket, non-MAO-A and MAO-B inhibitor of LSD1. 19 In the present studies, we determined the chromatin-modifying as well as the in vitro and in vivo anti-AML activity of SP2509 against cultured and primary human AML cells. Recently, treatment with a pan-HDAC inhibitor (HDI) was also shown to downregulate LSD1 through Sp1 inhibition. 20 In AML cells, the pan-HDI panobinostat (PS) was also shown to increase H3K4Me3 plus inhibit H3K27Me3 levels, inducing p21 (CDKN1A), p15 (CDKN2B) and p16 (CDKN2A), as well as inhibiting cell cycle progression and promoting differentiation and apoptosis in AML cells. 21, 22 Therefore, in the present studies, we also determined the in vitro and in vivo anti-AML activity of co-treatment with SP2509 and PS. Our findings demonstrate that the combined treatment exerts synergistic in vitro activity against cultured and primary AML progenitor/stem cells. In addition, as compared with each agent alone, co-treatment with SP2509 and PS significantly improved the survival of immune-depleted mice engrafted with cultured or primary human AML cells.
MATERIALS AND METHODS

Reagents and antibodies
LSD1 antagonist, SP2509 and its inactive enantiomer, SP2513, were kindly provided by Salarius Pharmaceuticals (Holladay, UT, USA). PS was provided by Novartis Pharmaceuticals Inc. (East Hanover, NJ, USA). Anti-H3K4Me3, H3K9Me2 and H3K27Me3 antibodies for chromatin immunoprecipitation were obtained from Millipore (Billerica, MA, USA). Anti-LSD1, cleaved poly (ADP-ribose) polymerase, anti-c-MYC and anti-BIM antibodies were obtained from Cell Signaling (Danvers, MA, USA). Anti-p21WAF antibody was obtained from Neomarkers (Fremont, CA, USA). Anti-p27KIP antibody was obtained from BD Biosciences (San Jose, CA, USA). Anti-CoREST antibody was obtained from Abcam (Cambridge, MA, USA) Anti-b-actin antibody and lentiviral short hairpin RNAs (shRNAs) targeting LSD1 or nontargeting shRNA were obtained from Sigma-Aldrich (St Louis, MO, USA).
SP2509 activity assays
The LSD1 screening biochemical assay kit was purchased from Cayman Chemical (Ann Arbor, MI, USA). Test compounds were diluted to 20 Â the desired test concentration in 100% dimethyl sulfoxide and 2.5 ml of the diluted drug sample was added to a black 384-well plate. The LSD1 enzyme stock was diluted 17-fold with assay buffer and 40 ml of the diluted LSD1 enzyme was added to the appropriate wells. Substrate, consisting of horseradish peroxidase, dimethyl K4 peptide corresponding to the first 21 amino acids of the N-terminal tail of histone H3, and 10-acetyl-3,7-dihydroxyphenoxazine was then added to wells. Resorufin was analyzed on an Envision plate reader (Perkin Elmer, Waltham, MA, USA) with an excitation wavelength of 530 nm and an emission wavelength of 595 nm. The activity of SP2509 on the other oxidases was determined by using commercially available kits. For determining the glucose oxidase activity (which also noncovalently binds FAD in an elongate conformation), the glucose oxidase kit used was procured from Life Technologies (Carlsbad, CA, USA; catalog number A22189). The MAO assays were performed using the MAO-glo kit (Promega V1401, Madison, WI, USA) with MAO-A from Promega (V1452) and MAO-B from Sigma (M7441-1VL, St Louis, MO, USA).
Cell culture OCI-AML3 and MOLM13 cells were obtained from the DSMZ (Braunschweig, Germany) and cultured in the recommended media. MV4-11 cells were obtained from the American Type Culture Collection (Manassas, VA, USA) and cultured in the recommended media. All experiments with cell lines were performed within 6 months after thawing or obtaining from the American Type Culture Collection or DSMZ. Cell line authentication was performed by the American Type Culture Collection or DSMZ. The American Type Culture Collection and DSMZ use short tandem repeat profiling for characterization and authentication of cell lines.
Primary normal progenitor and AML blast progenitor cells
Primary peripheral blood and/or bone marrow aspirate AML samples were obtained and prepared for the studies below, as previously described. 22, 23 Banked, de-linked and de-identified, normal or AML CD34 þ or AML CD34 þ CD38 À LIN À bone marrow progenitor/stem cells were purified, as previously described. 21, 22 Assessment of apoptosis by Annexin V staining Untreated or drug-treated cells were stained with Annexin V (Pharmingen, San Diego, CA, USA) and TO-PRO-3 iodide and the percentages of apoptotic cells were determined by flow cytometry, as previously described. 23, 24 The combination index for each drug combination and the evaluation of the synergistic interactions were calculated by median dose effect analyses (assuming mutual exclusivity) utilizing the commercially available software Calcusyn (Biosoft, Ferguson, MO, USA). 25 Combination index values of less than 1.0 represent a synergistic interaction of the two drugs in the combination.
Assessment of percentage nonviable cells
Following designated treatments, cells were washed with 1 Â phosphatebuffered saline (PBS), stained with propidium iodide and analyzed by flow cytometry, as previously described. 23, 24 Assessment of differentiation and CD86 expression Following designated treatments, cells were washed with 1 Â PBS, and then incubated in 0.2% bovine serum albumin/PBS with IgG isotype control, anti-CD11b, anti-CD14 or anti-CD86 antibodies in the dark at 4 1C for 30 min. Cells were washed with 0.2% bovine serum albumin/PBS and the percentage of CD11b, CD14 or CD86-positive cells was determined by flow cytometry. 23, 26 For determination of CD68 expression, cells were fixed with paraformaldehyde, permeabilized with methanol and incubated in 0.2% bovine serum albumin/PBS with IgG isotype control or anti-CD68 antibody in the dark at 4 1C for 30 min. Cells were washed with 0.2% bovine serum albumin/PBS and the percentage of CD68-positive cells was determined by flow cytometry. For assessment of morphological differentiation of cultured and primary AML cells, cells were cytospun onto glass slides for 5 min. Cells were stained with hematoxylin and eosin and the cells were observed by light microscopy. The percentage of morphological differentiation was determined by counting 100-200 cells on the slides. 23 Colony growth assay Cultured AML cells were treated with SP2509 and/or PS for 48 h. At the end of treatment, cells were washed free of the drugs and 500 cells per condition were plated in methylcellulose and incubated at 37 1C. Colony formation was measured 7-10 days after plating. 23, 24 Chromatin immunoprecipitation and real-time PCR OCI-AML3 and MOLM13 cells were treated with SP2509 for 16 h. Following drug exposure, cross-linking, cell lysis, sonication and chromatin immunoprecipitation for 3MeK4 Histone H3, 2MeK9 Histone H3 or 3MeK27 Histone H3 was performed according to the manufacturer's protocol (Millipore). For quantitative assessment of p57KIP, KLF4 and p21 promoter DNA in the chromatin immunoprecipitates, a SYBR Green Mastermix from Applied Biosystems (Foster City, CA, USA) was used. Relative enrichment of the promoter DNA in the chromatin immunoprecipitates was normalized against the amount of p57KIP, KLF4 and p21 promoter DNA in the input samples. 22, 27 RNA isolation and quantitative PCR Following the designated treatments with SP2509, total RNA was isolated with a High Pure RNA isolation kit (Roche Diagnostics, Indianapolis, IN, USA) and reverse transcribed. Quantitative real-time PCR analysis for the expression of p57KIP, KLF4 and p21 was performed on complementary DNA using TaqMan probes from Applied Biosystems. 22, 23 Relative mRNA expression was normalized to the expression of glyceraldehyde 3-phosphate dehydrogenase.
shRNA to LSD1 Lentiviral shRNAs targeting LSD1 or nontargeting shRNA were procured from Sigma-Aldrich and transduced into OCI-AML3 cells, as previously described. 23 Forty-eight hours post transduction, the cells were washed with complete media and plated with or without PS for 48 h for assessing apoptosis, cell proliferation or colony growth.
Cell lysis, protein quantification and immunoblot analyses Untreated or drug-treated cells were centrifuged, and the cell pellets were lysed and the protein quantification and immunoblot analyses were performed, as previously described. [22] [23] [24] Immunoblot analyses were performed at least twice and representative immunoblots are shown.
In vivo model of AML All in vivo studies were approved by, and conducted in accordance with the guidelines of the Institutional Animal Care and Use Committees at the Houston Methodist Research Institute. Female NOD/SCID mice were exposed to 2.5 Gy of radiation. The following day, 5 million OCI-AML3 cells were injected into the lateral tail vein of the mice and the mice were monitored for 7 days. Following treatments were administered in cohorts LSD1 antagonist and HDAC inhibitor against AML cells W Fiskus et al of eight mice for each treatment: vehicle alone, 25 mg/kg SP2509, 5 mg/kg PS and SP2509 plus PS. Treatments were initiated on day 7 for OCI-AML3 cells. SP2509 (formulated in solubilization buffer (20% Cremaphor, 20% dimethyl sulfoxide, 60% sterile water)) was administered twice per week (Tuesday and Thursday) intraperitoneally for 3 weeks, and then discontinued. PS (formulated in 5% dimethyl sulfoxide/95% normal saline) was administered by intraperitoneally injection 3 days per week (Monday, Wednesday, Friday) for 3 weeks and discontinued. The survival of mice is represented by a Kaplan-Meier survival plot. 22, 23 The doses of PS used in these studies were determined to be safe and effective through previously reported studies. 22 A separate in vivo experiment was conducted using NSG mice and primary AML cells. 28, 29 Following engraftment of the AML cells (presence of greater than 1% CD45 þ cells in the peripheral blood), mice were treated with SP2509 and/or PS, as described above, for 3 weeks. 9, 29 The survival of mice is represented by a Kaplan-Meier plot.
Statistical analysis
Significant differences between values obtained in a population of AML cells treated with different experimental conditions were determined using a two-tailed, paired t-test or a one-way analysis of variance within an analysis package of Microsoft Excel 2010 software or using GraphPad Prism (GraphPad Software Inc., CA, USA). P-values of less than 0.05 were assigned significance. Statistical differences in the survival of the mice treated with SP2509, PS or SP2509 þ PS were determined by log-rank (Mantel-Cox) test. P-values of less than 0.05 were assigned significance.
RESULTS
SP2509 inhibits LSD1 activity, reduces colony growth and induces apoptosis of cultured AML cells Utilizing a cell-free in vitro assay, we first determined the activity of SP2509 against a variety of oxidases including the MAOs A and B (MAO-A and MAO-B) (Figures 1a and b)
. SP2509 was found to selectively inhibit LSD1 at low nanomolar concentrations ( Figure 1b) . The 50% inhibitory concentration of SP2509 against LSD1 was determined to be 13 nM. SP2509 was inactive against MAO-A, MAO-B, lactate dehydrogenase and glucose oxidase. We next determined the ability of SP2509 to induce apoptosis in cultured AML cells. As shown in Figure 1c , treatment with SP2509 for 48 h dose dependently induced modest levels of apoptosis in AML cells ( Figure 1c ). However, OCI-AML3 cells, which are known to express mutant NPM1 and DNMT3A, 23 were significantly more sensitive than the other AML cell types (Po0.05). As determined by propidium iodide uptake and flow cytometry, following 96 h of exposure to SP2509, OCI-AML3 cells also exhibited the highest loss of viability compared with the other AML cell types ( Figure 1d SP2509 treatment inhibits the association of LSD1 with CoREST, increases promoter-specific H3K4Me3 and induces p53, p21 and C/EBPa in AML cells Turning to the chromatin effects of SP2509, using chromatin immunoprecipitation analysis with anti-H3K4Me3 antibody, we determined the effect of SP2509 treatment on the levels of H3K4Me3 that was associated with the chromatin of the known LSD1 target gene promoters, for example, those of p57KIP, KLF4 and p21. Treatment with SP2509 increased the level of H3K4Me3 from 1.7-fold (p57KIP and KLF4) to 3.5-fold (CDKN1 A, p21) associated with the chromatin of these gene promoters in OCI-AML3 (Figure 2a ). SP2509 treatment also increased the H3K9Me2 levels (Supplementary Figure 2) but did not alter the H3K27Me3 levels associated with the promoters of these genes (Figure 2b) . Consistent with this, SP2509 treatment also increased the mRNA levels of p57KIP, KLF4 and p21 in a dose-dependent manner, with the maximum increase observed for the mRNA of p21, following exposure to SP2509 for 16 h (Figure 2c ). Treatment with SP2509 exerted similar effects on the chromatin alterations and the mRNA levels in MOLM13 cells (Supplementary Figures 3A and B) . We also determined whether treatment with SP2509 affected the association of LSD1 with the corepressor CoREST in the cultured AML cells. As shown in Figure 3a , SP2509 treatment disrupted the association of LSD1 with CoREST in OCI-AML3 and MOLM13 cells, without affecting the levels of LSD1. Concomitantly, treatment with SP2509 also induced the protein levels of p53 and p21, as well as of the myeloid differentiation-associated transcription factor CCAAT/enhancer binding protein a (C/EBPa) in the AML cells (Figure 3b ).
Treatment with SP2509 induces differentiation of cultured and primary AML cells Previous reports have demonstrated that treatment with the nonspecific LSD1 antagonist TCP or a biguanide polyamine analog induces myelo-monocytic differentiation-associated markers and induces the morphologic features of differentiation in AML cells. 17 On the basis of this and prompted by the observation that SP2509 treatment induced p21 levels and increased the expression of C/EBPa, we determined the ability of SP2509 to induce differentiation in AML cells. Treatment with SP2509 increased the expression of the myelo-monocytic differentiation marker CD11b, with only a minimal increase in the expression of CD68 in OCI-AML3 cells (Figure 4a ). In contrast, exposure to SP2509 increased the expression of CD14 and CD68 in MOLM13 cells (Figure 4b ). MOLM13 cells do not express CD11b, and SP2509 treatment did not induce its expression in MOLM13 cells. Unlike what has been previously reported, SP2509 treatment did not increase the expression of CD86 in OCI-AML3 or MOLM13 cells (Supplementary Figure 4) . 26 Treatment with SP2509 also increased the expression of CD11b and CD14 in four separate samples of primary AML blasts expressing NPM1c þ and/or FLT3-ITD (Figure 4c ). Importantly, SP2509 treatment also induced the morphological features of differentiation in OCI-AML3 and MOLM13 cells, as exemplified in Figure 4d . Exposure to SP2509 also dose dependently induced morphological features of differentiation in the primary AML blasts (Figure 4e ), as also exemplified and presented in Figure 4f . Induction of the morphological features of differentiation is regarded as the 'gold standard' of evidence for differentiation in the myeloid lineage AML cells.
Targeted knockdown of LSD1 mimics the anti-AML activity of SP2509 To confirm that the effects of SP2509 on the AML cells was due to SP2509-mediated inhibition of LSD1, we also determined the effect of the shRNA-mediated genetic knockdown of LSD1 in OCI-AML3 cells. As compared with the nontargeted (NT) control shRNA, the LSD1-targeted shRNA knocked down the expression of LSD1 by B50% (Figure 5a ). Consistent with the previous reports documenting that LSD1 stabilizes DNMT1 levels, 15 targeted knock down of LSD1 also depleted DNMT1 in OCI-AML3 cells (Figure 5a ). Attenuation of LSD1 was associated with increase in the levels of global histone H3K4Me2, H3K4Me3 and H3K9Me2, but depletion in the levels of c-Myc protein (Figure 5a ). Lentiviral transduction of LSD1 shRNA in OCI-AML3 cells resulted in decline in the suspension culture growth over 96 h (Figure 5b ) and colony culture growth in semisolid medium over 10 days (Figure 5c ). It is noteworthy that, compared with OCI-AML3 cells transduced by the NT shRNA, SP2509 treatment-induced expression of CD11b and the loss of viability was significantly abrogated in OCI-AML3 cells transduced by the shRNA to LSD1 (Figures 5d and e) . This indicated that the differentiation and loss of viability mediated by SP2509 was at least partly mediated through inhibition of LSD1.
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Co-treatment with SP2509 and PS exerts synergistic lethal activity against cultured and primary AML cells Next, on the basis of the observation that pan-HDIs induce differentiation and apoptosis, as well as deplete LSD1 levels in AML cells, 20, 22 we determined the effects of co-treatment with PS on the anti-AML activity of SP2509. In these studies, we used relatively lower concentrations of PS that are well tolerated (5-15 nM), but biologically effective as epigenetic modifiers. (Figure 6c and Supplementary Figures 5A-C) . As compared with treatment with each agent alone, co-treatment with PS and SP2509 was also associated with greater increase in the levels of p21, p27, BIM and cleaved poly (ADP-ribose) polymerase (Figure 6d ). We also determined whether exposure to PS and SP2509 more than each agent alone induced biomarkers associated with induction of myeloid differentiation in the cultured AML cells. As shown in Supplementary  Figures 6A and B , compared with treatment with each agent alone, co-treatment with SP2509 and PS for 96 h induced higher levels of p21, p16 and C/EBPa, as well as induced higher levels of CD11b in OCI-AML3 cells (Po0.05). We next determined the lethal effects of SP2509 and/or PS against patient-derived, CD34 þ primary AML versus normal bone marrow progenitor cells. 
viability of the primary AML versus normal progenitor cells. Furthermore, co-treatment with the combination was significantly more lethal against AML versus normal progenitor cells (Po0.01; Figure 7a ). In addition, compared with each agent alone, co-treatment with SP2509 and PS caused more loss of viability of the primary AML progenitor cells. This was associated with greater depletion of c-Myc but induction of p21, p27 and BIM in the AML progenitor cells (Figure 7b ). We next determined whether the combination was also highly active against the purified CD34 þ CD38 À LIN À primary AML stem/progenitor cells. As shown in Figure 7c and Supplementary Figure 5D , co-treatment with SP2509 and PS was synergistically lethal against the AML stem/progenitor cells. 
Combined treatment with SP2509 and PS exerts superior in vivo activity against AML xenografts and 'primagrafts' We next determined the in vivo anti-AML activity of SP2509 and/or PS against cultured (OCI-AML3) in NOD/SCID mice, as well as against primary AML blasts engrafted in the bone marrow, that is, 'primagrafts' in the NSG mice. 29 Following the tail vein infusion and engraftment of OCI-AML3 cells, the effect of the treatment with the vehicle control, PS or SP2509 alone, or the combination of SP2509 and PS, for 3 weeks on the survival of the NOD/SCID mice was determined. The Kaplan-Meier plot depicting the survival of the mice demonstrates that, as compared with treatment with the vehicle alone, treatment with either SP2509 or PS significantly improved the median survival of the mice infused with OCI-AML3 cells (37 and 36.5 days, respectively, versus 19.5 days for vehicle control) (Po0.05; Figure 7d) . Notably, combined treatment with PS and SP2509 further improved the median survival of the mice (44.5 days), as compared with treatment with SP2509 or PS alone (Po0.01). One-third of the mice co-treated with SP2509 and PS were alive 80 days following the infusion of the AML cells. Figure 7e demonstrates the effects of SP2509 and/or PS on the survival of NSG mice engrafted with the primary AML blasts co-expressing FLT3-ITD and NPM1c þ . As shown, treatment with SP2509 or PS alone for 3 weeks significantly improved the median survival of the mice, as compared with the treatment with vehicle control (Po0.01). Combined therapy with SP2509 and PS was superior to the treatment with SP2509 or PS alone in improving the median survival of the mice (95 versus 80 and 56 days, respectively; Po0.01), with 50% of the mice surviving more than 100 days after the infusion of the AML blasts in the tail veins of the mice. This plateau in the survival curve suggests a potentially curative impact of the combination on the survival of the mice (Figure 7e ). We also determined the ex vivo sensitivity of the primary AML sample utilized as the primagraft in the NSG mice. As shown in Supplementary Figure 7A , co-treatment with SP2509 and PS induced more apoptosis than either agent alone. Ex vivo cotreatment with SP2509 and PS also synergistically induced apoptosis of the primary AML cells with combination indices o1.0, as determined by median dose effect and isobologram analysis (Supplementary Figure 7B) . 
DISCUSSION
In the present studies, we demonstrate for the first time that a novel, potent LSD1 antagonist SP2509, induces growth inhibition, differentiation and apoptosis in human AML cells. Importantly, unlike the reported experience with the TCP analogs, exposure to SP2509 did not induce toxicity in immune-depleted mice engrafted with AML at doses that exerted anti-AML activity. Consistent with the previous report demonstrating that LSD1 is essential for the survival of MLL-AF9-expressing leukemia stem cells, our findings show that inhibition of LSD1 is lethal against AML expressing MLL fusion oncoprotein. Moreover, our studies also demonstrate that SP2509 is relatively more active in inducing loss of viability of OCI-AML3 cells expressing mutant NPM1, which had not been previously reported. SP2509 treatment also exhibited in vivo anti-AML activity in immune-depleted mice engrafted with OCI-AML3 cells or primary AML blasts expressing mutant NPM1 plus FLT3-ITD, without inducing any toxicity in the mice, which was noted with the use of TCP or its analogs as the LSD1 antagonist. 17, 18 SP2509 is a small molecule reversible inhibitor of LSD1. 19 It showed activity at low nanomolar levels against LSD1 in the cellfree in vitro enzyme assay, but exerted the biological activity in the AML cells at the micromolar level. This is similar to what has been previously reported. 19 Unlike the situation in the cell-free enzyme assay, the lower intracellular potency of SP2509 is likely due to the presence and activity of LSD1 in the regulatory protein complexes in the intracellular setting, and the potential regulation of the biological outcome of LSD1 inhibition by other intracellular factors. 9, 10, 19 For example, the demethylase activity of LSD1 at the nucleosomes is enhanced by its association with the corepressor complexes such as Co-REST and NURD. 9, 19, 32 Our studies also show that the binding of LSD1 and CoREST is partially disrupted by SP2509 treatment. Inhibition of LSD1 by SP2509 resulted in an increase in the promoter-specific, permissive H3K4Me3 modification, as well as induced p53, p21 and C/EBPa levels. Whether this was due to transcriptional and/or post-transcriptional effects was not determined here; however, these alterations due to SP2509 treatment were clearly associated with growth inhibition, differentiation and the loss of viability of the AML cells. An inverse correlation of LSD1 levels with differentiation has also been reported in neuroblastoma cells. 33 In a separate report, alteration in the expression of the Myc 'core module' genes was identified in the leukemia stem cells in which LSD1 was knocked down. 
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In this report, the knockdown and inhibition of LSD1 was also shown to inhibit growth and induce differentiation of AML progenitor cells expressing MLL fusion oncoprotein. 18 We also determined that the biological effects of SP2509 treatment were also phenocopied by shRNA-mediated knockdown of LSD1 in AML cells, suggesting that the effects of SP2509 were mediated by LSD1 inhibition. Recent reports have highlighted that the NPM1 mutation is the founder mutation in the AML stem/progenitor cells where acquisition of FLT3-ITD mutation results in the emergence of an aggressive AML phenotype. 4, 34 In our studies, SP2509 exerted a relatively higher level of activity against AML cells expressing NPM1 mutation. Although the precise mechanism underlying this was not further probed here, a clear role of LSD1-dependent demethylase activity has been demonstrated in normal differentiation and in regulating cell death upon differentiation of stem/progenitor cells. 14, 35, 36 In addition, LSD1-associated corepressor complexes have been implicated in TAL1 and Notch signaling, which are also involved in regulating the biology of hematopoietic stem/progenitor cells. [37] [38] [39] Consistent with this, our findings show that SP2509 exerted in vitro and in vivo anti-AML activity especially against the leukemia-initiating primary AML progenitor/stem cells co-expressing NPM1 and FLT3 mutations.
A previous study demonstrated that co-treatment with LSD1 antagonist enhanced the differentiation inducing activity of alltrans-retinoic acid against AML cells.
17 LSD1-associated CoREST and NURD complexes also contain class I HDAC-associated HDAC activity. 9, 10, 19, 32 Consistent with this, and with our previously reported findings that treatment with pan-HDI PS induces differentiation in AML blast progenitor cells, 22 our present in vitro findings confirm that co-treatment with SP2509 or knockdown of LSD1 by shRNA enhanced the lethal effects of relatively low and clinically achievable concentrations of PS in AML cells. 30, 31 We also demonstrate here that co-treatment with SP2509 and PS was associated with greater induction of the markers of myeloid differentiation in AML cells, which could potentially contribute to the superior anti-AML activity of the combination. Moreover, we observed synergistic apoptotic effects of SP2509 and PS against cultured and primary AML cells. This may be explained by greater induction of the levels of pro-apoptotic proteins p27 and BIM in AML cells exposed to cotreatment with SP2509 and PS, as compared with each drug alone. 40, 41 Previous reports have identified that LSD1-mediated histone demethylation triggers Myc-induced transcription, and the Myc 'core module' gene expression was altered in the leukemia stem cells in which LSD1 was knocked down. 
Here, we also noted that synergistic activity of co-treatment with SP2509 and PS was associated with a greater depletion of c-Myc expression in the primary AML blast progenitor cells expressing mutant NPM1. Although other reports have shown that combined inhibition of LSD1 and HDACs achieves superior antitumor activity against glioblastoma and breast cancer cells, 43, 44 in these reports, the LSD1 antagonists employed are known to be either irreversible LSD1 inhibitors 45 or exhibit intolerable in vivo activity in the mouse models of AML where these inhibitors were studied. 17, 18 In contrast, our in vivo studies demonstrate that co-treatment with SP2509 and PS yields significantly better survival without inducing toxicity, and suggests a potential for cure of the immune-depleted mice engrafted with AML cells expressing NPM1 mutation irrespective of the co-expression of FLT3-ITD. Collectively, these findings strongly support the rationale for further in vivo testing of SP2509-based combination with pan-HDI such as PS against AML, especially those expressing NPM1 mutation. 
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